Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19SARS-CoV-2 감염 및 COVID-19 치료를 위한 HIV 프로테아제 억제제 및 뉴클레오타이드 RNA 폴리머라제 억제제 재배치Review Published on 2021-03-042022-08-31 Journal: European Journal of Clinical Pharmacology [Category] SARS, 신약개발, 임상, 치료제, [키워드] addition antiretroviral Antiviral treatment approved approved drug candidate Candidates Clinical studies clinical study clinical trial clinical trials clinician Cobicistat compounds COVID-19 darunavir darunavir/cobicistat drug drugs evaluate evaluated Favipiravir followed by high variability HIV protease inhibitor HIV protease inhibitors Hospitalization indications inhibitors lack Lopinavir Lopinavir/ritonavir MERS Mortality pandemic Prevalence Protease inhibitor protease inhibitors question Remdesivir repositioning Repositioning drugs Research Result Ritonavir RNA polymerase RNA polymerase inhibitor RNA polymerase inhibitors RNA virus SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 pandemic single-stranded RNA virus sofosbuvir Study design Taking target tenofovir the SARS-CoV-2 therapeutic options Therapeutics Treatment treatment of COVID-19 Vaccine [DOI] 10.1007/s00228-021-03108-x PMC 바로가기 [Article Type] Review
Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19Correspondence Published on 2021-03-012022-10-05 Journal: Journal of Clinical and Experimental Hepatology [Category] 신약개발, 치료제, [키워드] Against COVID-19 daclatasvir hepatitis C repurposing SARS-CoV-2 sofosbuvir [DOI] 10.1016/j.jceh.2020.10.001 [Article Type] Correspondence
Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other CoronavirusesSARS-CoV-2 및 기타 코로나바이러스와의 싸움에서 약물로서의 뉴클레오사이드 유사체 및 뉴클레오사이드 전구체Review Published on 2021-02-132022-08-31 Journal: Molecules [Category] MERS, 신약개발, 치료제, [키워드] active against acute respiratory syndrome approach China colds common colds coronavirus coronavirus disease CoV COVID-19 CoVs derivative drug effective drug effective drugs effective therapy Epidemics family Coronaviridae Favipiravir focus growth HCoV Health Organization human CoV humans Infection infections inhibit lead main mechanism mammal mammals mass vaccination MERS MERS-CoV Middle East Middle East respiratory syndrome Mild molnupiravir nucleoside nucleoside drugs nucleosides Other pandemic positive result positive-sense precursor provide Remdesivir respiratory respiratory diseases respiratory infections responsible ribavirin RNA SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severe respiratory disease severe respiratory diseases sofosbuvir Spread the SARS-CoV-2 therapy upper respiratory infection vaccination Viral diseases virus viruses while WHO World Health Organization [DOI] 10.3390/molecules26040986 PMC 바로가기 [Article Type] Review
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysisCOVID-19 치료를 위한 Sofosbuvir/daclatasvir 요법: 개별 환자 데이터 메타 분석Meta-Analysis Published on 2021-01-192022-09-11 Journal: Journal of Antimicrobial Chemotherapy [Category] 임상, 치료제, [키워드] 95% CI all-cause mortality Analysis antiviral activity approach Arm ARMS baseline characteristics Characteristics clinical Clinical outcome clinical outcomes clinical recovery clinical trial Combination comparator control arm daclatasvir eight Evidence HCV hospitalized COVID-19 patient hospitalized COVID-19 patients IMPROVE in vitro study inclusion criteria Meta-analysis moderate to severe non-randomized patient data patients patients with moderate Primary outcome Primary outcomes random-effect randomization Randomized Randomized controlled trials regimen risk risk ratio safety profile Sample size SARS-CoV-2 severe COVID-19 significantly lower sofosbuvir sofosbuvir/daclatasvir survival Treatment Trial was used [DOI] 10.1093/jac/dkaa418 PMC 바로가기 [Article Type] Meta-Analysis
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro , in vivo , and clinical trials중증급성호흡기증후군(SARS), 중동호흡기증후군(MERS), 코로나바이러스 감염증 2019(COVID-19)의 치료: 시험관 내, 생체 내 및 임상 시험에 대한 체계적인 검토Review Published on 2021-01-012022-09-10 Journal: Theranostics [Category] MERS, 비임상, 신약개발, 임상, 치료제, [키워드] acute respiratory syndrome article breath Clinical studies clinical study clinical trial Colchicine conducted controlled trials Convalescent plasma therapy coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 daclatasvir disease effective eight English Evidence help highlight identify in vitro In vitro studies in vivo information investigated MERS Meta-analysis Middle East Middle East respiratory syndrome Mortality Other outcome participant patients positive provide Randomized controlled trial rationale RCT RCTs Remdesivir required Research respiratory SARS Screening searched Severe acute respiratory syndrome sofosbuvir sofosbuvir/daclatasvir Spread syndrome systematic review therapeutic therapeutic agent therapeutic agents therapeutic effect therapy treating COVID-19 Treatment [DOI] 10.7150/thno.48342 PMC 바로가기 [Article Type] Review
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2SARS-CoV-2의 박테리아 인공 염색체(BAC) 벡터 비감염성 복제Article Published on 2021-01-012022-09-11 Journal: Antiviral Research [Category] SARS, 치료제, [키워드] Antiviral antiviral agent Antiviral agents antiviral protein BAC Bacterial bacterial artificial chromosome biosafety biosafety level cell lines chromosome COVID-19 pandemic daclatasvir desired mutation desired mutations envelope facilitate hepatitis C hepatitis C virus IFN-α in viral In-vitro inhibitor Interferon alpha membrane nCoV overexpression Plasmid Protein Remdesivir replicated Replication replicon reporter reporter gene RNA SARS-CoV-2 secreted sofosbuvir structural genes subgenomic mRNA transfection Viral viral subgenomic mRNA Virus-host interactions ZAP Zinc [DOI] 10.1016/j.antiviral.2020.104974 PMC 바로가기 [Article Type] Article
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysisCOVID-19 치료를 위한 약리학적 중재의 비교 효능 및 안전성: 체계적인 검토 및 네트워크 메타 분석Meta-Analysis Published on 2020-12-302022-08-13 Journal: PLoS Medicine [Category] Biology and Life Sciences, MERS, meta-analysis, 임상, [키워드] 1.26 95% CI 95% confidence interval Admission aggravation Alpha Anakinra analyses Analysis anti-inflammatory agent anti-inflammatory agents Asia assessment associations Azithromycin benefit Cardiac complications cardiac safety risk cardiac safety risks cardiac-impaired population cardiac-impaired populations carried categories category Causality certainty clinical clinical benefit clinical benefits Clinical outcome clinical settings clinical trial ClinicalTrials clinician Cochrane Library collected Combination Comparative controlled trials convalescent plasma coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids Course COVID-19 COVID-19 disease COVID-19 disease course COVID-19 treatments CRD42020186527 Critically ill Critically ill patient critically ill patients daclatasvir dataset determine development disease course drug effective Efficacy and safety eligibility criteria eligible Europe evaluate Evidence evidence of fatal cardiac complication fatal cardiac complications Google Scholar help heterogeneous High-dose Hospitalization hospitalized COVID-19 patients Hydroxychloroquine ICU Immunoglobulin information intensive care intensive care unit interferon interferon-alpha Intravenous immunoglobulin investigated itolizumab Ivermectin IVIG Level management mechanical ventilation medRxiv Meta-analysis Middle East mild patients moderate moderate to severe moderate/high evidence certainty Mortality mortality rate mortality rates Network meta-analysis NMA non-ICU non-ICU setting noncardiac serious adverse events North America Numerous observational studies observational study Odds ratio outcome Patient patients hospitalized pharmacological agent pharmacological intervention pharmacological interventions pharmacological management plasma Policy populations Potential treatment potential treatments progression PROSPERO provide QT prolongation QT prolongation incidence Randomized controlled trial Randomized controlled trials randomized trial randomized trials RCT RCTs recommendations reduce reduce COVID-19 aggravation reduce mortality rate reduced reflected registry Remdesivir Research researcher Result risk risk of bia RoB RoB2 ROBINS-I framework searched self-limiting disease Serious Adverse Event Serious Adverse Events severe COVID-19 patient severe disease severe pneumonia shown significantly sofosbuvir sofosbuvir plus daclatasvir South America SSRN standard care Study protocol supported systematic review systematic synthesis Tocilizumab translated Treatment treatment regimen viral clearance rate vulnerable population WHO WHO International Clinical Trials Registry Platform [DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
Repurposing Nucleoside Analogs for Human CoronavirusesArticle Published on 2020-10-292023-07-02 Journal: Antimicrobial Agents and Chemotherapy [Category] SARS, [키워드] Antiviral agents Coronaviridae COVID-19 emtricitabine HCoV-OC43 lamivudine nucleoside analogs Remdesivir SARS-CoV-2 sofosbuvir [DOI] 10.1128/AAC.01652-20 PMC 바로가기
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by RemdesivirArticle Published on 2020-10-062022-10-04 Journal: Scientific Reports [Category] MERS, SARS, 치료제, [키워드] activity Antiviral Biochemistry Brain Chemical biology clinical trial clinical trials Combination Coronavirus replication COVID-19 daclatasvir demonstrated DNA polymerase drug Drug discovery effective EPCLUSA exonuclease genetics Hepatitis hepatitis C virus inhibit SARS-CoV-2 inhibitor initiated investigator lung maintain molecular molecular basis offer Other pandemic polymerase Proofreading RdRP RdRps Replication responsible resulting RNA RNA-dependent RNA polymerase SARS-CoV SARS-CoV-2 sofosbuvir Structure the SARS-CoV-2 therapeutic viral genome [DOI] 10.1038/s41598-020-73641-9 PMC 바로가기 [Article Type] Article
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein–Drug and Protein–Protein Structures: An Analysis of Kinetically Active ResiduesArticle Published on 2020-09-212022-10-28 Journal: Biomolecules [Category] COVID-19, SARS, [키워드] α-difluoromethylornithine (DMFO) active sites Analysis applied approach approved drug boceprevir Chloroquine Community COVID-19 drug drug design facilitate hydrophobic IMPROVE in silico include interactions Ivermectin molecular normal-modes Potential Potential treatment Protein protein–drug interactions Proteins Recognition Remdesivir residue small molecule sofosbuvir spike glycoprotein virus [DOI] 10.3390/biom10091346 PMC 바로가기 [Article Type] Article